Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago. These figures ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus ...

"The [sell-side indicator] has been a reliable contrarian indicator. In other words, it has been bullish when Wall Street was ...